Table 5.
Studies assessing sarcopenia in patients undergoing Sorafenib therapy
| Author (year) | Region | N. patients | Outcome | Methods | N. sarcopenic | Cut off |
|---|---|---|---|---|---|---|
| Mir (2012) [16] | Europe | 40 | Dose limiting toxicities | L3-SMI | 11 |
M: < 55.4 cm2/m2 F: < 38.9 cm2/m2 |
| Imai (2015) [66] | Asia | 40 | Mortality | L3-SMI | 15 | < 29.2 cm2/m2 |
| Nishikawa (2017) [67] | Asia | 232 |
OS Progression-free survival |
L3-SMI | 151 |
M: < 36.2 cm2/m2 F: < 29.6 cm2/m2 |
| Hiraoka (2017) [68] | Asia | 93 |
OS Time to progression Time on treatment |
PSI | 20 |
M: < 4.24 cm2/m2 F: < 2.50 cm2/m2 |
| Yamashima (2017) [69] | Asia | 40 |
OS Progression free survival |
ΔTPMT/height | – | 0.59 mm/m |
| Takada (2018) [70] | Asia | 214 | OS | L3-SMI | 123 |
M: < 42 cm2/m2 F: < 38 cm2/m2 |
| Antonelli (2018) [15] | Europe | 96 |
OS Time on treatment |
L3-SMI | 47 |
M: < 53 cm2/m2 if BMI > 25 < 43 cm2/m2 if BMI < 25 W: < 41 cm2/m2 |
| Saeki (2018) [71] | Asia | 100 | OS |
L3-SMI VFA |
46 |
M: < 42 cm2/m2 F: < 38 cm2/m2 VFA > 100 cm2 |
| Imai (2019) [72] | Asia | 61 | OS |
L3-SMI ΔVFMI, ΔSFMI, ΔL3-SMI |
25 before sorafenib |
M: < 42 cm2/m2 F: < 38 cm2/m2 ΔL3SMI > -5.73 cm2/m2/120 days ΔSFMI > -5.33 cm2/m2/120 days ∆VFMI > − 3.95 cm2/m2/120 days |
N Number, L3 third lumbar vertebra, SMI cross-sectional areas of skeletal muscle (cm2)/patient’s height (m2), OS Overall Survival, PSI psoas muscle area at level of middle of third lumbar vertebra (cm2) / height (m2), TPMT/height Transversal psoas muscle thickness (mm)/ height (m), VFA Visceral fat area, VFMI visceral fat mass index, SFMI subcutaneous fat mass index